GlassScriptPhysician profile
Manmohan K Katapadi
NPI 1528192820
$123,800.43
in general payments reported to CMS, 2019-2025
49 companies · $26K in 2025
The $26K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $26K · 2021: $20K · 2022: $19K · 2023: $9,930 · 2024: $12K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Food and Beverage: $8,205 · Travel and Lodging: $4,841 · Consulting Fee: $4,470 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,098.00 |
| Food and Beverage | $8,204.90 |
| Travel and Lodging | $4,840.94 |
| Consulting Fee | $4,470.00 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $54,328.69 | 2019-2025 | |
| Esperion Therapeutics, INC. | $33,757.73 | 2020-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $10,320.52 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $7,568.08 | 2019-2025 | Farxiga, Brilinta, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,921.29 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $3,299.79 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Janssen Pharmaceuticals, INC | $1,463.30 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $1,167.88 | 2019-2025 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $905.54 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $539.01 | 2019-2025 | Evkeeza |
| Amgen INC. | $522.48 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $520.58 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $500.20 | 2019-2024 | Lifevest |
| Amarin Pharma, INC. | $480.83 | 2019-2022 | |
| Astellas Pharma US INC | $434.29 | 2019-2022 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $430.02 | 2019-2024 | Tyvaso, Orenitram, Remodulin |
| E.R. Squibb & Sons, L.L.C. | $274.52 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $223.92 | 2019-2024 | Wegovy, Ozempic |
| Impulse Dynamics (USA) INC. | $164.85 | 2022-2025 | Optimizer, Optimizer |
| Alnylam Pharmaceuticals INC. | $151.89 | 2020-2024 | Onpattro |
| Abiomed | $150.33 | 2024-2025 | Impella |
| Boston Scientific Corporation | $145.10 | 2019-2025 | Cds - Mct/Cem Monitoring, Bodyguardian |
| Bardy Diagnostics, INC. | $145.00 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $142.15 | 2023-2024 | Inpefa |
| Abbott Laboratories | $123.92 | 2019-2022 | |
| Ge Healthcare | $105.74 | 2025 | |
| Cvrx, INC. | $101.84 | 2023-2024 | Barostim Neo System |
| Vital Connect, INC | $90.56 | 2023-2025 | Vitalpatch Rtm |
| Edwards Lifesciences Corporation | $83.54 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $81.86 | 2021-2023 | Arcalyst |
| Amryt Pharma Holdings LTD | $62.33 | 2021-2023 | Juxtapid |
| Biotronik INC. | $59.35 | 2019-2020 | |
| Lundbeck LLC | $58.59 | 2019-2020 | |
| Chiesi USA, INC. | $58.07 | 2023-2025 | Juxtapid, Kengreal |
| Akcea Therapeutics, INC. | $55.05 | 2019-2020 | |
| Inspire Medical Systems, INC. | $40.80 | 2025 | Inspire |
| Arbor Pharmaceuticals, INC. | $39.20 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $39.00 | 2023 | Edarbyclor |
| Philips North America LLC | $38.27 | 2024-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Ck4) Mcot |
| Scpharmaceuticals INC. | $37.65 | 2023 | |
| Vifor Pharma, INC. | $24.54 | 2019 | |
| Itamar Medical INC | $23.95 | 2022 | |
| Medicomp INC | $21.42 | 2023 | Telepatch Cardiac Monitor |
| Daiichi Sankyo INC. | $19.75 | 2025 | Injectafer |
| Mannkind Corporation | $17.38 | 2025 | |
| Medtronic, INC. | $16.38 | 2023 | Closurefast |
| Kowa Pharmaceuticals America, INC. | $15.43 | 2021 | |
| Baxter Healthcare | $14.32 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Kestra Medical Technology Services, INC. | $13.50 | 2025 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manmohan Katapadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.